Erythropoietin (Epo)
belongs to the most occupied growth factor in biomedical studies. It implicates
over 29,207 such studies at present; the 3.45% at least of which concern tissueischemia-reperfusion (IR) models.
 |
| Uterus Congestion |
A popular aim of Epo usage
is the reverse potency of IR transient injuries of organs, including their
tissues and certainly patients' health. However, satisfactory responses have
not yet been received concerning basic affairs, such as, the dosage height, the
administration timing, and the action velocity. The knowledge must be promoted
besides the original action of Epo in red blood cells production. These
specific matters require more detailed management.
No comments:
Post a Comment